Upload
amber-acosta
View
226
Download
0
Embed Size (px)
Citation preview
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 1/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
NOSC on its evolutionary journey
The Neuro-Oncology Scientific Club (NOSC)
put forward its aims and started its journey
about a year ago. This budding self centered
club got strong support and received
passionate attitude from the neuro-oncology
experts in the field. Experts from brain
tumor allied disciplines who have the
shared aim of “ serving brain tumor patients
better”, decided to unite within this
interdisciplinary scientific club.
The vision and mission of NOSC has been
providing a common place to cement the
links between neuro-oncology related
specialties and strengthening cross
disciplinary partnership to further help
brain tumor patients’ care in Iran,
respectively. In NOSC, members share their
experience in brain tumor care and science
so that together find out how their brain
tumor patients’ survival and quality of life
may further improve.
NOSC also tries to cater the needs of young
scholars and specialists with brain tumor
interest such as radiation oncologists, hem-
oncologist, radiologists, neurologists,
pathologists, etc. through providing high
quality educational case studies, reports and
presentations during the interval (seasonal)
sessions.
Like the so far conducted meetings, theoutcome report of forthcoming sessions and
future communications will be composed
for submission for possible publication in
international peer reviewed journals.
Adding to the above NOSC will pursue its aim to:
1. Report interesting brain tumor cases ofeducational value (NOSC case studyperiodical)2. Acting as a provincial and later on,national guideline definition group for braintumor diagnosis, management and followup.3. Organizing patients’ awarenesscampaigns and support programs.
Each provincial NOSC comprises regular
members, lead faculty and a chairing panel.
Contents:
NOSC on its evolutionary journey
The second NOSC meet-up in Mashhad
NOSC’s International visibility and exposure
NOSC Case Study Periodical
Congress links and neuro-oncology event updates
NOSC and the national scientific societies support
BRAIN TUMOR
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 2/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
The panel leads the discussions flow, lead
faculty may be speakers and members share
ideas and contribute.
There has been two fruitful sessions in
Mashhad and one in Tehran so far.
The scientific report of the first two
meetings got published in the following peer
reviewed international journals:
Anvari K., et al. Towards the Real
Interdisciplinary Approach in Treating
Brain Tumors: Report from the Neuro-
Oncology Scientific Club opening meeting -
NOSC 2011-13 October- Mashhad, IR Iran
WMC ONCOLOGY2011;2(1):WMC002381
http://www.webmedcentral.com/wmcpdf/
Article_WMC002381.pdf
Haddad P., et al. Turning Interdisciplinary
Brain Tumor Science into Survival; Report
from the Neuro-Oncology Scientific Club
Opening Session- NOSC 2012 -19 January-
Tehran, IR Iran. Report and Opinion,
2012;4:(2):42-53http://www.sciencepub.net/report/report0402/
007_8292report0402_42_53.pdf
NOSC is grateful to see specialist from
brain tumor related deciplines who continue
to join and expand provincial forums in
Tehran, Mashhad, Isfahan, Shiraz and
Tabriz. They mean to make NOSC not only a
transparent interdisciplinary discussion
forum, but also a practical platform for“serving better, together!”
The second NOSC meet-up in Mashhad
The second Mashhad NOSC meet-up ( NOSC-2) was conducted on 19th April 2012, in Pardisan
hotel, Mashhad. There were around 50 attendees ( 84% of the invitees participated). During this
lively and active meeting, radiation oncologists together with others discussed applicable
clauses of ESMO and NCCN guidelines in their current practice for high grade glioma brain
tumor patients. Neurosurgeons actively participated and discussed with oncologists and others,the future strategies for brain tumor patients referral and bidirectional collaborations. Adding to
these, Neurologists put forward discussions on anticonvulsant prophylaxis and further.
Amongst panelist, there were pathology and radiology experts discussing with others the
relevant issues. Moreover, fundamentals of translational research on medical genetics in GBM
were argued and agreed upon.During this meeting the final draft of the provincial brain tumor
registry software( PBTR) as well as NOSC case study Periodical details were communicated.
Forthcoming Mashhad NOSC was proposed to be in early October 2012.
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 3/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
This meeting was again a leap forward to let NOSC’s plans turn into practice.
The outcome report of the 2nd Mashhad NOSC meeting ( NOSC-2) is now published in the
IJMCR ( International Journal of Medical and Clinical Research) under the contributors’ names.
IJMCR is a peer reviewed journal published by Bioinfo International (ranked 8 th worldwide by-
Index Copernicus )Source: http://journals.indexcopernicus.com/toprankpubl.php
IJMCR has obtained impact value (ICV) of 4.47 by Index Copernicus. This journal is currently
indexed with Index Copernicus, EBSCO, ProQuest, DOAJ, LWW, Ovid, Scopus and Chemical
Abstract Services. The CAB abstracts are available in Thomson Web of Knowledge- ISI.
Source1:http://journals.indexcopernicus.com/masterlist.php?name=Master&litera=I&start=420&skok=30
Source 2: http://www.bioinfo.in/index.php
Anvari K., et al. (2012) From Fundamental Brain Tumor Science to Interdisciplinary bedside
Care; the Outcome Report from the Neuro-Oncology Scientific Club Second meet-up (NOSC-
2), 19th April 2012, Mashhad, Iran. International Journal of Medical and Clinical Research,
ISSN:0976-5530 & E-ISSN:0976-5549, Volume 3, Issue 5, pp.-168-175.
To view the journal-issue front page please click:http://www.bioinfo.in/journalvolume.php?id=39&month=6&year=2012
To retrieve the full paper’s PDF please check:
http://www.bioinfo.in/uploadfiles/13415739563_5_2_IJMCR.pdf
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 4/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
International visibility and exposure
NOSC and the ISPNO 2012, Toronto, Canada
This was another remarkable achievement in making NOSC more visible and practical.Tehran NOSC’s first discussion forum report, got accepted as a poster abstract in the 15thISPNO congress, June 24-27 2012, Toronto, Ontario, Canada .Congress site: http://www.ispno2012.com/abstract
This meeting hosted oncologists, neurosurgeons, radiation oncologists, neurologists, nurses, basic researchers, neuro-pathologists, neuro-radiologists, endocrinologists, psychologists, social workers, rehabilitation specialist and other professionals involved in the care of patients withcentral nervous system tumors.This meeting was sponsored and conducted by SNO (The Society for NeouroOncology).Together with all other abstracts, this is now published in the journal of Neuro-Oncology,
under “Neuro-Oncology in developing countries “ section.Journal’s data:
Impact-factor:111 5.483 5-Yr impact factor: 6.043 | PubMed central
To view the abstract follow the below link:http://neuro-oncology.oxfordjournals.org/content/14/suppl_1/i106.abstract
Citation: Neuro Oncol (2012) 14 (suppl 1): i106-i110. doi: 10.1093/neuonc/nos094
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 5/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
NOSC- Brain tumor registry proposal abstract and the EANO ( European Association of Neuro-Oncology)
The 10th Congress of the European
Association of NeuroOncology, will be held
in September 6-9, 2012 in Marseille, France, we are pleased to inform all NOSC members
that NOSC’s proposal abstract entitled
‘Neuro-Oncology Scientific Club and the
Iranian Brain Tumor Registry’ (Control
Number 2012-A-5-EANO) is accepted as a
poster communication to be presented at
this meeting.
Congress link: www.eano2012.eu
This means that the idea and content of the
brain tumor registry software which has
already been developed is ratified by the
EANO scientific committee.
The first interesting case is shared by 3 experts from radiation oncology, radiology and
neurology field in Tehran. The case details are being composed for submission for
possible publication in a case study journal. We’d like to herewith invite NOSC
contributors to share their interesting brain tumor ( mainly high grade glioma) cases
with the editorial committee of NOSC case study periodical.
What’s new about the
“NOSC Case Study Periodical”
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 6/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
“NOSC case study Periodical” will be particularly interested to publish cases on the
followings:
- Newly diagnosed GBM
- Interdisciplinary success in management of complex cases
- Learning from errors
- Rare presentations- Unexpected outcome ( positive or negative) after chemoradiation with
Temozolomide
- Adverse events seen with various therapeutic regimens.
The received case details will be analyzed and documented as case reports for
submission for publication in peer reviewed journals under contributors’ names.
NOSC scientific service section and Behestan Darou’s medical division will be pleased to
render any assistance your paper requires for preparation and submission.
For further information about “NOSC Case Study Periodical” the authors’ guideline
kindly contact the editorial office:
02188774200 ext 1634
The PBTR software in its final format is in hand. This will be installed in selected centers
in Tehran and other main provinces as pilot. Possible deficiencies and neededamendments will be identified in its pilot phase and the software will be fine tuned for
final launch.
Congress links and neuro-oncology event updates
If you want to plan ahead for attendance in any of the cardinal neuro-oncology/oncology
conferences following links may be of help.
http://www.eortc.org/conferences-and-courses/eortc-eano-esmo-trends-central-nervous-system-malignancies
22-23 March 2013, Prague, Czech Republic
Provincial Brain Tumor Registry (PBTR)
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 7/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
http://congress.mums.ac.ir/uzyaci
NOSC is now being endorsed by and receiving patronage from
the national scientific societies
Recently it has been decided that a steering board comprising delegates from official national
scientific societies would define NOSC’s overall strategies and plan of action. This executive
decision was made once the scientific societies graciously showed their willingness to support
NOSC. The steering board members list is to be finalized, shortly. There will be 1-3 delegates
from each of the following societies. The first NOSC steering board meeting will be held in early
October 2012.
6-8 September 2012, Mashhad, Iran
http://www.ecco-org.eu/Conferences/ ESSO-32
SNO 17th Annual Scientific Meeting and
Education Day | 15-18 Nov. 2012
http://www.soc-neuro-onc.org/en/cev/76
Iranian Cancer AssociationIranian Association of Surgeons, Neurosurgery Branch
Iranian Society of Radiation Oncology
Cancer Research Network of Iran
Iranian society of pathology
Iranian Society of pediatric hematology and oncology
Iranian society of radiology
8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)
http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 8/8
NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com
TEMODAL
Indication
TEMODAL (temozolomide) is indicated for the treatment of adult patients with newly diagnosed glioblastomamultiforme concomitantly with radiotherapy and then as maintenance treatment.
Selected Important Safety InformationTEMODAL is contraindicated in patients who have a history of hypersensitivity (such as urticaria, allergic reactionincluding anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome) to any of its components, or toDTIC.
Patients treated with TEMODAL may experience myelosuppression including prolonged pancytopenia, which mayresult in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure toconcomitant medications associated with aplastic anemia including carbamazepine, phenytoin, andsulfamethoxazole/trimethoprim complicates assessment. Geriatric patients and women have been shown in clinicaltrials to have a higher risk of developing myelosuppression. Cases of myelodysplastic syndrome and secondarymalignancies, including myeloid leukemia, have also been observed.
Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving concomitantTEMODAL and radiotherapy for the 42-day regimen. There may be a higher occurrence of PCP whentemozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide,particularly patients receiving steroids, should be observed closely for the development of PCP regardless ofthe regimen.
TEMODAR can cause fetal harm when administered to a pregnant woman. In nursing women, a decision should bemade whether to discontinue nursing or to discontinue TEMODAL, taking into account the importance of the drug tothe mother. The safety and effectiveness of TEMODAL in children have not been established.
As bioequivalence between TEMODAL Capsules and TEMODAL for Injection has been established only whenTEMODAL for Injection was given over 90 minutes, infusion over a shorter or longer period of time may result insuboptimal dosing. Additionally, the possibility of an increase in infusion-related adverse reactions cannot be ruled out.
TEMODAL Capsules should not be opened or chewed. If capsules are accidentally opened or damaged, rigorousprecautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucousmembranes.
Caution should be exercised when administered to those with severe hepatic or renal impairment.
The adverse event profile was similar in patients <65 years of age and those > 65 years.
The most common adverse reactions in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAL) and theMaintenance Phase (TEMODAL alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%;vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; rash 19%, 13%; constipation 18%, 22%; with thefollowing important adverse events also reported: convulsions 6%, 11% and thrombocytopenia 4%, 8%.
Of these adverse events, those grade > 3 in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAL)and the Maintenance Phase (TEMODAL alone), respectively, were fatigue 7%, 9%; nausea 1%, 1%; vomiting <1%,2%; anorexia 1%, 1%; headache 2%, 4%; rash 1%, 1%; constipation 1%, 0%; convulsions 3%, 3%; thrombocytopenia3%, 4%.
When laboratory abnormalities and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and
Grade 3 or 4 platelet abnormalities, including thrombocytopenic events, occurred in 14% of patients treated withtemozolomide.
Adverse reactions reported from intravenous formulation studies that were not reported in TEMODAL Capsule studieswere: pain, irritation, pruritus, warmth, swelling, and erythema at infusion site as well as the following adversereactions: petechiae and hematoma.
Before prescribing TEMODAL, please read the Prescribing Information.
Source: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000229/WC500035621.pdf